Karsten Weller

Karsten Weller

Auto-generated profile, based on publicly available information

Karsten Weller

Institute of Allergology, Charité – Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin and Humboldt‐Universität zu Berlin Berlin Germany

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2022 in Allergy
Verified
Journal Article
Open access
PDF file
MMMarcus Maurer
Marcus Maurer
MMMarkus Magerl
Markus Magerl
SBStephen Betschel
Stephen Betschel
WAWerner Aberer
Werner Aberer
IAIgnacio J. Ansotegui
Ignacio J. Ansotegui
TCTimothy Craig
Timothy Craig
Hereditary angioedema (HAE) is a rare and disabling disease for which early diagnosis and effective therapy are critical. This revision and update of the global WAO/EAACI guideline on the diagnosis and management of HAE provides up‐to‐date guidance for the management of HAE. For this update and revision of the guideline, an international panel of experts reviewed the existing evidence, developed 28 recommendations, and established consensus by an online DELPHI process. The goal of these recommendations and guideline is to help physicians and their patients in making rational decisions in the management of HAE with deficient C1 inhibitor (type 1) and HAE with dysfunctional C1 inhibitor (type 2), by providing guidance on common and important clinical issues, such as: (1) How should HAE be diagnosed? (2) When should HAE patients receive prophylactic on top of on‐demand treatment and what treatments should be used? (3) What are the goals of treatment? (4) Should HAE management be different for special HAE patient groups such as children or pregnant/breast‐feeding women? and (5) How should HAE patients monitor their disease activity, impact, and control? It is also the intention of this guideline to help establish global standards for the management of HAE and to encourage and facilitate the use of recommended diagnostics and therapies for all patients.

8 September 2019 in Allergy
Verified
Journal Article
Open access
PDF file
JFJulia Fricke
Julia Fricke
GÁGabriela Ávila
Gabriela Ávila
TKTheresa Keller
Theresa Keller
KWKarsten Weller
Karsten Weller
SLSusanne Lau
Susanne Lau
TKThomas Keil
Thomas Keil
Background and objectives: Urticaria is a frequent skin condition, but reliable prevalence estimates from population studies particularly of the chronic form are scarce. The objective of this study was to systematically evaluate and summarize the prevalence of chronic urticaria by evaluating population‐based studies worldwide.Methods: We performed a systematic search in PUBMED and EMBASE for population‐based studies of cross‐sectional or cohort design and studies based on health insurance/system databases. Risk of bias was assessed using a specific tool for prevalence studies. For meta‐analysis, we used a random effects model.Results: Eighteen studies were included in the systematic evaluation and 11 in the meta‐analysis including data from over 86 000 000 participants. Risk of bias was mainly moderate, whereas the statistical heterogeneity (I2) between the studies was high. Asian studies combined showed a higher point prevalence of chronic urticaria (1.4%, 95%‐CI 0.5‐2.9) than those from Europe (0.5%, 0.2‐1.0) and Northern American (0.1%, 0.1‐0.1). Women were slightly more affected than men, whereas in children < 15 years we did not find a sex‐specific difference in the prevalence. The four studies that examined time trends indicated an increasing prevalence of chronic urticaria over time.Conclusions: On a global level, the prevalence of chronic urticaria showed considerable regional differences. There is a need to obtain more sex‐specific population‐based and standardized international data particularly for children and adolescents, different chronic urticaria subtypes and potential risk and protective factors.

10 July 2017 in Allergy
Verified
Journal Article
Open access
PDF file
MMMarcus Maurer
Marcus Maurer
MAM. Abuzakouk
M. Abuzakouk
FBF. Bérard
F. Bérard
Giorgio Walter CanonicaGiorgio Walter Canonica
Giorgio Walter Canonica
HEH. Oude Elberink
H. Oude Elberink
MBM.‐M. Balp
M.‐M. Balp
Background: Chronic spontaneous urticaria (CSU) can be debilitating, difficult to treat, and frustrating for patients and physicians. Real‐world evidence for the burden of CSU is limited. The objective of this study was to document disease duration, treatment history, and disease activity, as well as impact on health‐related quality of life (HRQoL) and work among patients with inadequately controlled CSU, and to describe its humanistic, societal, and economic burden.Methods: This international observational study assessed a cohort of 673 adult patients with CSU whose symptoms persisted for ≥12 months despite treatment. Demographics, disease characteristics, and healthcare resource use in the previous 12 months were collected from medical records. Patient‐reported data on urticaria and angioedema symptoms, HRQoL, and work productivity and activity impairment were collected from a survey and a diary.Results: Almost 50% of patients had moderate‐to‐severe disease activity as reported by Urticaria Activity Score. Mean (SD) Dermatology Life Quality Index and Chronic Urticaria Quality of Life Questionnaire scores were 9.1 (6.62) and 33.6 (20.99), respectively. Chronic spontaneous urticaria markedly interfered with sleep and daily activities. Angioedema in the previous 12 months was reported by 66% of enrolled patients and significantly affected HRQoL. More than 20% of patients reported ≥1 hour per week of missed work; productivity impairment was 27%. These effects increased with increasing disease activity. Significant healthcare resources and costs were incurred to treat CSU.Conclusions: Chronic spontaneous urticaria has considerable humanistic and economic impacts. Patients with greater disease activity and with angioedema experience greater HRQoL impairments.

13 June 2016 in Allergy
Verified
Journal Article
Closed access
PDF file
KWKarsten Weller
Karsten Weller
MMMarkus Magerl
Markus Magerl
APAdriane Peveling‐Oberhag
Adriane Peveling‐Oberhag
PMPeter Martus
Peter Martus
PSPetra Staubach
Petra Staubach
MMMarcus Maurer
Marcus Maurer

1 July 2018 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
THTomasz Hawro
Tomasz Hawro
TOTatevik Ohanyan
Tatevik Ohanyan
NSNicole Schoepke
Nicole Schoepke
MMMartin Metz
Martin Metz
APAdriane Peveling-Oberhag
Adriane Peveling-Oberhag
KWKarsten Weller
Karsten Weller

1 June 2020 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
KWKarsten Weller
Karsten Weller
TDTamara Donoso
Tamara Donoso
MMMarkus Magerl
Markus Magerl
EAEmel Aygören-Pürsün
Emel Aygören-Pürsün
PSPetra Staubach
Petra Staubach
MMMarcus Maurer
Marcus Maurer